Forxiga (dapagliflozin) is a selective and reversible inhibitor of human sodiumglucose co-transporter 2 (SGLT2 inhibitor) indicated as an adjunct to diet and exercise as a once daily oral medication to improve glycaemic control in adult patients with Type 2 diabetes mellitus as add on combination therapy or as monotherapy in metformin intolerant patients.

Product Information – European Medicines Agency